Clinical Trial Update: EBRT + Lu-PSMA for N1M0 Prostate Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the combination of external beam radiation therapy (EBRT) with Lutetium-177 PSMA-617 (Lu-PSMA) for N1M0 prostate cancer has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Lu-PSMA-617 (lutetium-177-PSMA-617)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Prostatic Neoplasm | Phase 1 | Status: COMPLETED